



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit
<b>First Implementation Date:</b>	October 20, 2022
<b>Revised Date:</b>	N/A
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input checked="" type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors.

**Why Issue Selected:** Janus kinase (JAK) is a group of cytoplasmic protein tyrosine kinases that are essential for signal transduction to the nucleus from common plasma membrane receptors for some interleukins. JAKs are comprised of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2). Inhibition of these enzymes results in decreased cytokine or growth factor-mediated gene expression and intracellular activity leading to reduced immunological responses. Jakafi® (ruxolitinib) was FDA-approved in 2011 and is currently indicated for intermediate and high-risk myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease. Inrebic® (fedratinib) was approved by the FDA in 2019 for the indication of intermediate or high-risk myelofibrosis. Vonjo® was FDA-approved in 2022 for the indication of intermediate or high-risk myelofibrosis in adults with a platelet count below 50 x 10<sup>9</sup>/L. All three medications are available as oral formulations. Other JAK inhibitors differ slightly in their inhibition of the specific kinases and do not share any of the same indications as Jakafi, Inrebic, or Vonjo.

Due to the high cost and specific approved indications, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors.

**Program-Specific Information:**

Date Range FFS 1/1/21 to 12/31/21				
Drug	Claims	Spend	Cost per month (MAC)	Cost per year (MAC)
INREBIC 100 MG CAP	0	-	\$22,840.80	\$274,089.60
JAKAFI 5 MG TAB	63	\$666,504.41	\$15,514.80	\$186,177.60
JAKAFI 10 MG TAB	57	\$663,560.95		
JAKAFI 15 MG TAB	1	\$14,707.66		
JAKAFI 20 MG TAB	13	\$189,630.46		
JAKAFI 25 MG TAB	8	\$96,043.57		
VONJO 100 MG CAP	0	-	\$19,422.00	\$233,064.00

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List

*SmartPA Clinical Proposal Form*  
 © 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

**Appropriate Indications**

**Clinical Edit**

**Data Sources:**  **Only Administrative Databases**

**Databases + Prescriber-Supplied**

## Setting & Population

- Drug class for review: Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

### Initial Therapy:

- Prescribed by or in consultation with an appropriate specialist in the treated disease state **AND**
- Documented diagnosis of intermediate or high-risk myelofibrosis **AND**
  - Participant is aged at least 18 years **AND**
  - For Vonjo: documentation of platelet count  $< 50 \times 10^9/L$
  - For Inrebic: failure to achieve therapeutic response after minimum of 90 days of therapy with Jakafi
  - Initial approval is for 6 months
- Documented diagnosis of symptomatic low-risk myelofibrosis **AND**
  - For Jakafi only:
    - Participant is aged at least 18 years **AND**
    - Documented adequate therapeutic trial of hydroxyurea (3 claims in past 12 months) **AND**
    - Documented adequate therapeutic trial of peginterferon alfa-2a (3 claims in past 12 months)
    - Initial approval is for 6 months
- Documented diagnosis of polycythemia vera **AND**
  - For Jakafi only:
    - Participant is aged at least 18 years **AND**
    - Participant is considered high-risk based on
      - Age  $> 60$  years **OR**
      - Age  $\leq 60$  year and thrombosis history **AND**
    - Documented therapeutic trial of peginterferon alfa-2a (3 claims in past 12 months) **AND**
    - Patient must have resistance or intolerance to hydroxyurea defined by:
      - Need for phlebotomy to keep hematocrit  $< 45\%$  after 3 months of at least 2 g/day of hydroxyurea **OR**
      - Platelet count  $> 400 \times 10^9/L$  and white blood cell count  $> 10 \times 10^9/L$  after 3 months of at least 2 g/day of hydroxyurea **OR**
      - Reduction of splenomegaly  $< 50\%$  after 3 months of at least 2 g/day of hydroxyurea **OR**
      - Absolute neutrophil count  $< 1.0 \times 10^9/L$  or platelet count  $< 100 \times 10^9/L$  or hemoglobin  $< 10$  g/dL **OR**
      - Documentation of previous therapeutic trial (at least 3 months of therapy) or concurrent treatment, intolerance, insufficient response, or contraindication with hydroxyurea.
    - Initial approval for 6 months
- Documented diagnosis of acute graft-versus-host disease **AND**
  - For Jakafi only:
    - Participant is aged at least 12 years **AND**
    - Documentation that participant is steroid-refractory defined by:
      - Progression of acute GVHD within 3-5 days of therapy onset with  $\geq 2$  mg/kg/day of prednisone **OR**

*SmartPA Clinical Proposal Form*

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Failure to improve within 5-7 days of treatment initiation **OR**
- Incomplete response after more than 38 days of immunosuppressive treatment including steroids **OR**
- Documented ADE/ADR to oral corticosteroids
  - Initial approval for 6 months
- Documented diagnosis of chronic graft-versus-host disease **AND**
  - For Jakafi only:
    - Participant is aged at least 12 years **AND**
    - Documentation that participant is steroid-refractory defined by:
      - Chronic GVHD progression while on prednisone at  $\geq 1$  mg/kg/day for 1-2 weeks **OR**
      - Stable GVHD disease while on  $\geq 0.5$  mg/kg/day (or 1 mg/kg every other day) of prednisone for 1-2 months **OR**
      - Documented ADE/ADR to oral corticosteroids
      - Initial approval for 6 months

Continuation of Therapy

- Documented compliance to prescribed drug therapy (3 claims in past 120 days)
- Continued approval for up to 12 months

**Denial Criteria**

- Therapy will be denied if all approval criteria are not met
- Participant is currently pregnant

**Required Documentation**

Laboratory Results:   
 MedWatch Form:

Progress Notes:   
 Other:

**Disposition of Edit**

Denial: Exception code "0682" (Clinical Edit)  
 Rule Type: CE

**Default Approval Period**

6 months

**References**

- Inrebic (fedratinib) [package insert]. Summit, NJ: Celgene Corporation; December, 2021.
- Jakafi (ruxolitinib) [package insert]. Wilmington, DE: Incyte Corporation; September, 2021.
- Vonjo (pacritinib) [package insert]. Seattle, WA: CTI BioPharma Corporation; February, 2022.
- IPD Analytics: New Drug Review: Vonjo (pacritinib). Accessed April 22, 2022.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloproliferative Neoplasms. Version 2.2022 – April 13, 2022. [mpn.pdf \(nccn.org\)](https://www.nccn.org). Accessed April 22, 2022.

- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hematopoietic Cell Transplantation (HCT). Version 1.2022 – April 1, 2022. [hct.pdf \(nccn.org\)](#). Accessed April 22, 2022.